Candriam SCA’s BridgeBio Pharma BBIO Stock Holding History

Candriam SCA’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.4M	Buy	300,520 +21,632	+8%	+$1.52M	0.1%	190
2026 Q1	$20.7M	Hold	278,888	–	–	0.11%	190
2025 Q4	$21.3M	Buy	278,888 +129,902	+87%	+$8.53M	0.11%	182
2025 Q3	$7.74M	Buy	+148,986	New	+$7.27M	0.04%	304
2024 Q2	–	Sell	-380,000	Closed	-$11.7M	–	693
2024 Q1	$11.7M	Buy	380,000 +81,000	+27%	+$2.75M	0.08%	240
2023 Q4	$12.1M	Buy	299,000 +54,000	+22%	+$1.62M	0.08%	231
2023 Q3	$6.46M	Sell	245,000 -40,000	-14%	-$1.14M	0.05%	284
2023 Q2	$4.9M	Hold	285,000	–	–	0.04%	335
2023 Q1	$4.35M	Buy	285,000 +188,756	+196%	+$2.2M	0.03%	396
2022 Q4	$733K	Buy	96,244 +469	+0.5%	+$4.49K	﹤0.01%	758
2022 Q3	$952K	Sell	95,775 -306,137	-76%	-$3.18M	0.01%	717
2022 Q2	$3.65M	Hold	401,912	–	–	0.03%	376
2022 Q1	$4.08M	Hold	401,912	–	–	0.03%	392
2021 Q4	$6.7M	Sell	401,912 -53,373	-12%	-$2.26M	0.04%	306
2021 Q3	$21.3M	Hold	455,285	–	–	0.15%	166
2021 Q2	$27.8M	Buy	+455,285	New	+$26M	0.19%	124

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Candriam SCA's BBIO Position: Q2 2026 in Review

Candriam SCA increased its BridgeBio Pharma (BBIO) stake by 7.8% in Q2 2026, buying an estimated $1.52M and bringing the position to 300,520 shares worth $22.4M. The position accounts for 0.1% of the portfolio, ranked #190.

Candriam SCA first reported a position in BBIO in Q2 2021 and has held it in 16 quarters since. The position peaked at $27.8M in Q2 2021. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Candriam SCA held 300,520 shares of BridgeBio Pharma worth $22.4M as of Q2 2026.
Candriam SCA bought 21,632 BridgeBio Pharma shares in Q2 2026, an estimated $1.52M.
BridgeBio Pharma made up 0.1% of Candriam SCA's portfolio in Q2 2026, its #190 holding.
Candriam SCA first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 16 quarters since.
Candriam SCA's BridgeBio Pharma position peaked at $27.8M in Q2 2021.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.